
Dec 29 (Reuters) - Unicycive Therapeutics Inc UNCY.O:
UNICYCIVE THERAPEUTICS ANNOUNCES RESUBMISSION OF NEW DRUG APPLICATION (NDA) FOR OXYLANTHANUM CARBONATE (OLC)
UNICYCIVE THERAPEUTICS INC - NDA RESUBMITTED AFTER VENDOR RESOLVES FDA DEFICIENCIES
UNICYCIVE THERAPEUTICS INC - NDA SUBMISSION REVIEW EXPECTED WITHIN 6 MONTHS PER PRESCRIPTION DRUG USER FEE ACT